Polar Capital Biotech R Inc |
Performance History | 31/03/2024 |
Growth of 1,000 (EUR) |
Fund | 28.6 | 12.1 | -1.4 | 11.7 | 9.5 | |
+/-Cat | 9.4 | 15.1 | 11.3 | 10.6 | 5.8 | |
+/-Idx | 2.8 | 5.2 | 1.6 | 1.8 | -0.5 | |
Category: Sector Equity Biotechnology | ||||||
Benchmarks: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 22/04/2024 | USD 41.23 | |
Day Change | 1.12% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | IE00B3XLHR60 | |
Fund Size (Mil) 22/04/2024 | USD 1626.61 | |
Share Class Size (Mil) 22/04/2024 | USD 603.61 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 31/12/2023 | 1.62% |
Investment Objective: Polar Capital Biotech R Inc |
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. |
Returns | ||||||||||||||||
|
Management | ||
Manager Name Start Date | ||
David Pinniger 31/10/2013 | ||
Gareth Powell 31/10/2013 | ||
Inception Date 31/10/2013 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology NR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Polar Capital Biotech R Inc | 29/02/2024 |
|
|
Top 5 Holdings | Sector | % |
Regeneron Pharmaceuticals Inc | Healthcare | 6.59 |
Zealand Pharma A/S | Healthcare | 5.48 |
Celldex Therapeutics Inc | Healthcare | 4.78 |
argenx SE | Healthcare | 4.75 |
Blueprint Medicines Corp | Healthcare | 4.39 |
Increase Decrease New since last portfolio | ||
Polar Capital Biotech R Inc |